These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 15459003)
1. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. Strippoli GF; Craig M; Deeks JJ; Schena FP; Craig JC BMJ; 2004 Oct; 329(7470):828. PubMed ID: 15459003 [TBL] [Abstract][Full Text] [Related]
2. Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality and Renal Outcomes in Patients with Diabetes and Albuminuria: a Systematic Review and Meta-Analysis. Wang K; Hu J; Luo T; Wang Y; Yang S; Qing H; Cheng Q; Li Q Kidney Blood Press Res; 2018; 43(3):768-779. PubMed ID: 29794446 [TBL] [Abstract][Full Text] [Related]
3. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Strippoli GF; Bonifati C; Craig M; Navaneethan SD; Craig JC Cochrane Database Syst Rev; 2006 Oct; 2006(4):CD006257. PubMed ID: 17054288 [TBL] [Abstract][Full Text] [Related]
7. [Diabetic nephropathy and ACE inhibitors]. Amann B Clin Res Cardiol; 2006 Jan; 95 Suppl 1():i83-7. PubMed ID: 16598556 [TBL] [Abstract][Full Text] [Related]
8. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. Kshirsagar AV; Joy MS; Hogan SL; Falk RJ; Colindres RE Am J Kidney Dis; 2000 Apr; 35(4):695-707. PubMed ID: 10739792 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors. Crook ED; Preddie DC Ethn Dis; 2002; 12(4):S3-49-52. PubMed ID: 12477155 [TBL] [Abstract][Full Text] [Related]
10. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus. Hughes DB; Britton ML Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022 [TBL] [Abstract][Full Text] [Related]
11. Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients. Cooper ME J Hypertens Suppl; 1996 Dec; 14(6):S11-4. PubMed ID: 9023709 [TBL] [Abstract][Full Text] [Related]
12. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Casas JP; Chua W; Loukogeorgakis S; Vallance P; Smeeth L; Hingorani AD; MacAllister RJ Lancet; 2005 Dec; 366(9502):2026-33. PubMed ID: 16338452 [TBL] [Abstract][Full Text] [Related]
13. Role of blood pressure targets and specific antihypertensive agents used to prevent diabetic nephropathy and delay its progression. Strippoli GF; Craig MC; Schena FP; Craig JC J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S153-5. PubMed ID: 16565242 [TBL] [Abstract][Full Text] [Related]
14. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy. Pathak JV; Dass EE Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372 [TBL] [Abstract][Full Text] [Related]
15. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis. Sarafidis PA; Stafylas PC; Kanaki AI; Lasaridis AN Am J Hypertens; 2008 Aug; 21(8):922-9. PubMed ID: 18535536 [TBL] [Abstract][Full Text] [Related]
16. Impact of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on renal and mortality outcomes in people with Type 2 diabetes and proteinuria. Coleman CI; Weeda ER; Kharat A; Bookhart B; Baker WL Diabet Med; 2020 Jan; 37(1):44-52. PubMed ID: 31407377 [TBL] [Abstract][Full Text] [Related]
17. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option. Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075 [TBL] [Abstract][Full Text] [Related]
18. Treatment of diabetic nephropathy with angiotensin II receptor antagonist. Lewis EJ; Lewis JB Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737 [TBL] [Abstract][Full Text] [Related]
19. [Risk and prevention of diabetic nephropathy]. Ravera M; Re M; Deferrari G G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442 [TBL] [Abstract][Full Text] [Related]
20. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]